How much can people with type 1 diabetes benefit from adjunct therapies?

Friday, 23 September 2022, 08:30 - 09:30, Golgi Hall

Chairs: Chantal Mathieu, Belgium

Jerry R Greenfield, Australia: GLP-1 agonists

Parth Narendran, UK: SGLT2 inhibitors

Husam A Ghanim, USA: Combination therapy